Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit: MHRA Grilling Gives A Regulator's View Of The Stakes

This article was originally published in SRA

Executive Summary

Many of those in the life sciences sector who would be affected by a possible UK departure from the EU, including industry, scientists, the academic community and lawyers, have been happy to make their views known as to the likely effects. The voice of the drug regulators in this debate, though, has been understandably muted.

Advertisement

Related Content

UK Votes To Leave The EU – Where Next For The Life Sciences?
The Brexit Effect: What Would It Mean For Europe's Future Patent System?

Topics

Advertisement
UsernamePublicRestriction

Register

PS079347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel